The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: A historical - and futuristic - perspective

Journal of Neuro-Oncology

Volumn 75, Issue 3, 2005, Pages 253-266

  Finlay, Jonathan L ^a,b   Zacharoulis, Stergios ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Chemotherapy; Childhood malignant gliomas; Diffuse intrinsic pontine tumors (gliomas)

Indexed keywords

ANGIOGENESIS INHIBITOR; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; HYDROXYUREA; IMATINIB; LAPATINIB; LOMUSTINE; LONAFARNIB; METHYLPREDNISOLONE; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR; PREDNISONE; PROCARBAZINE; PROTEIN TYROSINE KINASE; RADIOSENSITIZING AGENT; RAS PROTEIN; TEMOZOLOMIDE; THIOTEPA; TIPIFARNIB; UNINDEXED DRUG; VASCULOTROPIN; VINCRISTINE;

ABDOMINAL PAIN; AGE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; BRAIN SURGERY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER MORTALITY; CANCER RADIOTHERAPY; CHILD CARE; CHILDHOOD CANCER; CLINICAL RESEARCH; CLINICAL TRIAL; DIARRHEA; DRUG MEGADOSE; DRUG TOLERABILITY; DYSPEPSIA; EDEMA; EVIDENCE BASED MEDICINE; FATIGUE; FEASIBILITY STUDY; GLIOMA; HEADACHE; HUMAN; LIVER DYSFUNCTION; MINIMAL RESIDUAL DISEASE; MORBIDITY; PONS ANGLE TUMOR; PROGNOSIS; RASH; REVIEW;

ADOLESCENT; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHILD; CLINICAL TRIALS; GLIOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTORY, 20TH CENTURY; HUMANS; MORBIDITY; MORTALITY; PATIENT SELECTION;

EID: 29744444959     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-005-6747-7     Document Type: Review

References (131)

1. JG Rosenstock AE Evans L Schut 1976 Response to vincristine of recurrent brain tumors in children J Neurosurg 45 135-140 939971 1:STN:280:CSmB3sbotVU%3D
2. BC Lampkin AM Mauer BH McBride 1967 Response of medulloblastoma to vincristine sulfate: A case report Pediatrics 39 761-763 6026877 1:STN:280:CCiC28flvFQ%3D
3. R Sposto IJ Ertel RD Jenkin CP Boesel JL Venes JA Ortega AE Evans W Wara D Hammond 1989 The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: Results of a randomized trial. A report from the Childrens Cancer Study Group J Neurooncol 7 165-177 2550594 1:STN:280:BiaA1c7nvFw%3D
4. Packer R, Sposto R, Finlay J, Boyett J: Survival of children with high-grade gliomas (HGG): A comparison of two sequential randomized CCG trials. Annual Meeting of the American Neurological Association, Washington, DC, October 1995, Ann Neurol 38: 343, 1995
5. TW Pendergrass JM Milstein JR Geyer AF Mulne EJ Kosnik JD Morris RL Heideman FB Ruymann JT Stuntz WA Bleyer 1987 Eight drugs in one day chemotherapy for brain tumors: Experience in 107 children and rationale for preradiation chemotherapy J Clin Oncol 5 1221-1231 3040919 1:STN:280:BiiA3M%2Fls1E%3D
6. JL Finlay JM Boyett AJ Yates JH Wisoff JM Milstein JR SJ Bertolone P McGuire JM Cherlow M Tefft et al 1995 Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group J Clin Oncol 13 112-123 7799011 1:STN:280:ByqD1MnptlI%3D
7. JH Wisoff JM Boyett MS Berger C Brant H Li AJ Yates P McGuire-Cullen PA Turski LN Sutton JC Allen RJ Packer JL Finlay 1998 Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: A report of the Children's Cancer Group trial no. CCG-945 J Neurosurg 89 52-59 9647172 1:STN:280:DyaK1czgvFertQ%3D%3D
8. Weisfeld-Adams J, Murphy D, Wisoff J, Sposto R, Young D, Finlay J: The impact of extent of surgical resection of consensus-reviewed pediatric intracranial high-grade gliomas on outcome: A report of the Children's Cancer Group trial. 11th International Symposium on Pediatric Neuro-oncology, Boston, June 2004 Neuro-oncology 6: 468, 2004
9. JW Campbell IF Pollack AJ Martinez B Shultz 1996 High-grade astrocytomas in children: Radiologically complete resection is associated with an excellent long-term prognosis Neurosurgery 38 258-264 8869052 1:STN:280:ByiD383mvFY%3D
10. RL Heideman J Kuttesch Jr AJ Gajjar AW Walter JJ Jenkins Y Li RA Sanford LE Kun 1997 Supratentorial malignant gliomas in childhood: A single institution perspective Cancer 80 497-504 10.1002/ (SICI)1097-0142(19970801)80:3<497::AID-CNCR18>3.0.CO;2-S 9241084 1:STN:280:ByiA1czgvFc%3D
11. JE Wolff AK Gnekow RD Kortmann T Pietsch C Urban N Graf J Kuhl 2002 Preradiation chemotherapy for pediatric patients with high-grade glioma Cancer 94 264-271 10.1002/cncr.10114 11815986 1:CAS:528:DC%2BD38XlslKntw%3D%3D
12. AL Albright R Sposto E Holmes PM Zeltzer JL Finlay JH Wisoff MS Berger RJ Packer IF Pollack 2000 Correlation of neurosurgical subspecialization with outcomes in children with malignant brain tumors Neurosurgery 47 879-885 11014428 1:STN:280:DC%2BD3cvmt1ektQ%3D%3D discussion 885-887
13. Batra V, Sposto R, Geyer J, Allen J, Pollack I, Finlay J: Long term outcome for children less than six years of age with diagnosis of consensus reviewed high-grade gliomas: A report of the CCG-945 study. International symposium on Pediatric Neuro-Oncology, Boston, Massachusetts, June 13-16, 2004; Neuro-Oncology 6: 450, 2004
14. Bouffet E, Sposto R, Allen J, Yates A, Pollack I, Finlay J: Outcome for children with consensus reviewed pathology of high grade gliomas of the spinal cord: A report on the CCG-945 study. International symposium on Pediatric Neuro-Oncology, Boston, Massachusetts, June 13-16, 2004; Neuro-Oncology 6: 450, 2004
15. Sapp M, Boyett J, Yates A, Burger P, Becker L, Davies R, Gilles F, Finlay J: Outcome for children with midline primary site high grade astrocytoma (HGA) treated on the Childrens Cancer Group Trial (CCG-945). Seventh International Symposium on Pediatric Neuro-oncology, Washington DC, May 1996 J Neuro-oncol 33: 269, 1996
16. SJ Bertolone AJ Yates JM Boyett D Wallace JL Finlay 2003 Combined modality therapy for poorly differentiated gliomas of the posterior fossa in children: A Children's Cancer Group report J Neurooncol 63 49-54 10.1023/A:1023774701112 12814254
17. M Fouladi DL Hunt IF Pollack G Dueckers PC Burger LE Becker AJ Yates FH Gilles RL Davis JM Boyett JL Finlay 2003 Outcome of children with centrally reviewed low-grade gliomas treated with chemotherapy with or without radiotherapy on Children's Cancer Group high-grade glioma study CCG-945 Cancer 98 1243-1252 12973849
18. IF Pollack JM Boyett AJ Yates PC Burger FH Gilles RL Davis JL Finlay 2003 The influence of central review on outcome associations in childhood malignant gliomas: Results from the CCG-945 experience Neuro-oncol 5 197-207 10.1215/S1152851703000097 12816726
19. Dufour C, Grill J, Lellouch-Tubiana A, Sainte-Rose C, Chastagner P, Frappaz D, Doz F, Pichon F, Raquin M, Kalifa C: High-grade gliomas (HGG) in children below 5 years of age: Results of chemotherapy only with BBSFOP protocol. A multi center trial of the French Society of Pediatric Oncology. International symposium on Pediatric Neuro-Oncology, Boston, Massachusetts, June 13-16 2004 Neuro-Oncology 6: 453, 2004
20. Hariharan S, Stuebgen P, Boyett JM, Yates AJ, Finlay JL, 1996. Anaplastic mixed gliomas in childhood: Results from the Childrens Cancer Group study, CCG-945. 32nd Annual Meeting of the American Society of Clinical Oncology, Philadelphia, PA, May 1996. Proc Am Soc Clin Oncol 15: 467, 1996
21. JR Geyer JL Finlay JM Boyett J Wisoff A Yates L Mao RJ Packer 1995 Survival of infants with malignant astrocytomas. A Report from the Childrens Cancer Group Cancer 75 1045-1050 7842407 1:STN:280:ByqC2cvms1E%3D
22. JC Allen S Aviner AJ Yates JM Boyett JM Cherlow PA Turski F Epstein JL Finlay 1998 Treatment of high-grade spinal cord astrocytoma of childhood with "8-in-1" chemotherapy and radiotherapy: A pilot study of CCG-945 Children's Cancer Group J Neurosurg 88 215-220 9452226 1:STN:280:DyaK1c7ht1Kjtw%3D%3D
23. JL Finlay JR Geyer PA Turski AJ Yates JM Boyett JC Allen RJ Packer 1994 Pre-irradiation chemotherapy in children with high-grade astrocytoma: tumor response to two cycles of the '8-drugs-in-1-day' regimen. A Childrens Cancer Group study, CCG-945 J Neurooncol 21 255-265 10.1007/ BF01063775 7699420 1:STN:280:ByqB3MznslQ%3D
24. IF Pollack SD Finkelstein J Woods J Burnham EJ Holmes RL Hamilton AJ Yates JM Boyett JL Finlay R Sposto 2002 Expression of p53 and prognosis in children with malignant gliomas N Engl J Med 346 420-427 10.1056/ NEJMoa012224 11832530 1:CAS:528:DC%2BD38XhtVWqu78%3D
25. IF Pollack RL Hamilton J Burnham EJ Holmes SD Finkelstein R Sposto AJ Yates JM Boyett JL Finlay 2002 Impact of proliferation index on outcome in childhood malignant gliomas: Results in a multi-institutional cohort Neurosurgery 50 1238-1244 12015841 discussion 1244-1245
26. IF Pollack SD Finkelstein J Burnham RL Hamilton AJ Yates EJ Holmes JM Boyett JL Finlay 2003 Association between chromosome 1p and 19q loss and outcome in pediatric malignant gliomas: Results from the CCG-945 cohort Pediatr Neurosurg 39 114-121 10.1159/000071647 12876389
27. E Arenson J Ater J Bank R Culler 1999 A randomized phase II Trial of high dose alkylating agents plus VP-16 in children with high grade astrocytoma J Pediatr Hematol Oncol 21 32510.1097/ 00043426-199907000-00085
28. Chintagumpala M, Burger P, McCluggage C, Kepner J, Thompson S, Michalski J, Blaney S, Woo S, Friedman H, Horowitz M: Response to Procarbazine in newly diagnosed patients with high grade glioma: A Pediatric Oncology Group (POG) Study. Thirty-Fifth Annual Meeting, ASCO, May 15-18, 1999 Atlanta, GA, ASCO Proc 18: 558a, 1999
29. Jakacki R, Prados M, Yates A, Timmerman R, Krailo M, Qu W, Adamson P, Pollack I, Children's Hospital of Pittsburgh P, PA: A phase I trial of temozolomide and CCNU in pediatric patients with newly diagnosed incompletely resected non-brain stem high grade gliomas: A Children's Oncology group study. International symposium on Pediatric Neuro-Oncology, Boston, Massachusetts, June 13-16 2004 Neuro-Oncology 6:459, 2004
30. E Bouffet C Mottolese A Jouvet I Philip D Frappaz C Carrie M Brunat-Mentigny 1997 Etoposide and thiotepa followed by ABMT (autologous bone marrow transplantation) in children and young adults with high-grade gliomas Eur J Cancer 33 91-95 9071906 1:CAS:528:DyaK2sXit1yitLY%3D
31. AC Grovas JM Boyett K Lindsley M Rosenblum AJ Yates JL Finlay 1999 Regimen-related toxicity of myeloablative chemotherapy with BCNU, thiotepa, and etoposide followed by autologous stem cell rescue for children with newly diagnosed glioblastoma multiforme: Report from the Children's Cancer Group Med Pediatr Oncol 33 83-87 10.1002/ (SICI)1096-911X(199908)33:2<83::AID-MPO4>3.0.CO;2-G 10398181 1:STN:280:DyaK1Mzis12nsw%3D%3D
32. V Papadakis IJ Dunkel LD Cramer E Kramer E Papadopoulos S Goldman RJ Packer M Willoughby D Baker J Garvin S Strandjord P Coccia AM Kaplan M Klemperer JL Finlay 2000 High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors Bone Marrow Transplant 26 153-160 10.1038/ sj.bmt.1702475 10918425 1:STN:280:DC%2BD3M%2FhvFCgsg%3D%3D
33. JL Finlay S Goldman MC Wong M Cairo J Garvin C August BH Cohen P Stanley RA Zimmerman B Bostrom JR Geyer RE Harris J Sanders AJ Yates JM Boyett RJ Packer 1996 Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group J Clin Oncol 14 2495-2503 8823328 1:CAS:528:DyaK28XlvVGju7o%3D
34. J Finlay C August R Packer R Zimmerman L Sutton A Freid L Rorke E Bayever N Kamani E Kramer B Cohen B Sturgill J SS Nachman P FS Turski S Steeves M Javid 1990 High-dose multi-agent chemotherapy followed by bone marrow "rescue" for malignant astrocytomas of childhood and adolescence J Neuro-Oncol 9 239-248 1:STN:280:By6B3c3it10%3D
35. Finlay J: High-dose chemotherapy with autologous marrow rescue (HDCx + ABMR) improves survival of patients with recurrent malignant glioma (MG) compared with conventional or no chemotherapy. 10th International Conference on Brain Tumor Research and Therapy, Voss, Norway, September 1993. J Neuro-Oncol, 15: Suppl S8, 1993
36. RL Heideman EC Douglass RA Krance J Fontanesi JA Langston RA Sanford EH Kovnar J Ochs J Kuttesch JJ Jenkins et al 1993 High-dose chemotherapy and autologous bone marrow rescue followed by interstitial and external-beam radiotherapy in newly diagnosed pediatric malignant gliomas J Clin Oncol 11 1458-1465 8336185 1:STN:280:ByyA38bkvVM%3D
37. Gardner S, Baker D, Belasco J, Phillips P, Bunin N, Grupp S, Iannone R, Knopp E, Miller D, Cervone K, Ngo H, Finlay J: Phase I dose escalation of temozolomide with thiotepa and carboplatin with autologous stem cell rescue (ASCR) in patients with recurrent/refractory central nervous system (CNS) tumors. International Symposium on Pediatric Neuro-Oncology, Boston, Massachusetts, June 13-16 2004 Neuro-Oncology 6: 455, 2004
38. MS Edwards WM Wara RC Urtasun M Prados VA Levin D Fulton CB Wilson J Hannigan P Silver 1989 Hyperfractionated radiation therapy for brain-stem glioma: A phase I-II trial J Neurosurg 70 691-700 2709109 1:STN:280:BiaB3MrpvFA%3D
39. RJ Packer JC Allen JL Goldwein J Newall RA Zimmerman J Priest T Tomita DE Mandelbaum BH Cohen JL Finlay et al 1990 Hyperfractionated radiotherapy for children with brainstem gliomas: A pilot study using 7,200 cGy Ann Neurol 27 167-173 10.1002/ana.410270212 2317012 1:STN:280:By%2BC1Mjhtlc%3D
40. RJ Packer RA Zimmerman A Kaplan WM Wara LB Rorke M Selch J Goldwein JA Allen J Boyett AL Albright et al 1993 Early cystic/necrotic changes after hyperfractionated radiation therapy in children with brain stem gliomas. Data from the Childrens Cancer Group Cancer 71 2666-2674 8453590 1:STN:280:ByyB3c7kvFw%3D
41. RJ Packer 1996 Brain stem gliomas: Therapeutic options at time of recurrence Pediatr Neurosurg 24 211-216 8873163 1:STN:280:ByiD38npvFA%3D
42. CR Freeman JP Krischer RA Sanford ME Cohen PC Burger R Carpio del EC Halperin L Munoz HS Friedman LE Kun 1993 Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: A Pediatric Oncology Group study Int J Radiat Oncol Biol Phys 27 197-206 8407392 1:STN:280:ByuD3M3gtFU%3D
43. MT Jennings R Sposto JM Boyett LG Vezina E Holmes MS Berger CS Bruggers JM Bruner KW Chan KE Dusenbery LJ Ettinger CR Fitz D Lafond DE Mandelbaum V Massey W McGuire L McNeely T Moulton IF Pollack V Shen 2002 Preradiation chemotherapy in primary high-risk brainstem tumors: Phase II study CCG-9941 of the Children's Cancer Group J Clin Oncol 20 3431-3437 10.1200/JCO.2002.04.109 12177103 1:CAS:528:DC%2BD38XntVyjsbk%3D
44. CS Kretschmar NJ Tarbell PD Barnes JP Krischer PC Burger L Kun 1993 Pre-irradiation chemotherapy and hyperfractionated radiation therapy 66 Gy for children with brain stem tumors. A phase II study of the Pediatric Oncology Group, Protocol 8833 Cancer 72 1404-1413 8339231 1:STN:280:ByyA3sfmtlU%3D
45. Korones DN, Kretschmar CS, Freeman CR, Fisher PG, Zhou T, Kepner J: Treatment of children with diffuse intrinsic brain stem glioma with standard dose irradiation and vincristine plus oral VP-16. A Pediatric Oncology Group study. Eighth Annual meeting of Society for Neuro-Oncology, Keystone, Colorado, November 13-16, 2003, Neuro-Oncology 5(4): 359, 2003
46. E Bouffet M Raquin F Doz JC Gentet C Rodary F Demeocq P Chastagner P Lutz O Hartmann C Kalifa 2000 Radiotherapy followed by high dose busulfan and thiotepa: A prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas Cancer 88 685-692 10.1002/(SICI)1097-0142(20000201)88:3<685::AID-CNCR27>3.0.CO;2-K 10649264 1:CAS:528:DC%2BD3cXptVartg%3D%3D
47. IJ Dunkel B O'Malley JL Finlay 1996 Is there a role for high-dose chemotherapy with stem cell rescue for brain stem tumors of childhood? Pediatr Neurosurg 24 263-266 8933570 1:STN:280:ByiD1cjlsl0%3D
48. IJ Dunkel JM Boyett A Yates M Rosenblum JH Garvin Jr BC Bostrom S Goldman LS Sender SL Gardner H Li JC Allen JL Finlay 1998 High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group J Clin Oncol 16 222-228 9440746 1:CAS:528:DyaK1cXmsVCqtg%3D%3D
49. IJ Dunkel JH Garvin Jr S Goldman LJ Ettinger AM Kaplan M Cairo H Li JM Boyett JL Finlay 1998 High dose chemotherapy with autologous bone marrow rescue for children with diffuse pontine brain stem tumors. Children's Cancer Group J Neurooncol 37 67-73 10.1023/A:1005874508975 9525840 1:STN:280:DyaK1c7osVOmtg%3D%3D
50. A Kedar BL Maria J Graham-Pole DM Ringdahl RG Quisling JP Mickle NP Mendenhall RB Marcus Jr S Gross 1994 High-dose chemotherapy with marrow reinfusion and hyperfractionated irradiation for children with high-risk brain tumors Med Pediatr Oncol 23 428-436 8084310 1:STN:280:ByuA28njs1E%3D
51. D Khuntia M Mehta 2004 Motexafin gadolinium: A clinical review of a novel radioenhancer for brain tumors Expert Rev Anticancer Ther 4 981-989 10.1586/14737140.4.6.981 15606327 1:CAS:528:DC%2BD2cXhtVyqtrvN
52. P Rodrigus 2003 Motexafin gadolinium: A possible new radiosensitiser Expert Opin Investig Drugs 12 1205-1210 10.1517/13543784.12.7.1205 12831354 1:CAS:528:DC%2BD3sXkvFegsbk%3D
53. S Rockwell ET Donnelly Y Liu LQ Tang 2002 Preliminary studies of the effects of gadolinium texaphyrin on the growth and radiosensitivity of EMT6 cells in vitro Int J Radiat Oncol Biol Phys 54 536-541 10.1016/ S0360-3016(02)02962-0 12243833 1:CAS:528:DC%2BD38XntVWqtL0%3D
54. S Xu K Zakian H Thaler C Matei A Alfieri Y Chen JA Koutcher 2001 Effects of Motexafin gadolinium on tumor metabolism and radiation sensitivity Int J Radiat Oncol Biol Phys 49 1381-1390 10.1016/S0360-3016(00)01566-2 11286846 1:CAS:528:DC%2BD3MXisVWnt74%3D
55. Evens AM, Lecane P, Magda D, Prachand S, Singhal S, Nelson J, Miller RA, Gartenhaus RB, Gordon LI: Motexafin gadolinium generates reactive oxygen species, induces apoptosis in sensitive and highly resistant multiple myeloma cells. Blood, 2004
56. H Dehnad HB Kal T Stam IS Gademan RJ Moorselaar van BP Sanden van der 2003 Response to motexafin gadolinium and ionizing radiation of experimental rat prostate and lung tumors Int J Radiat Oncol Biol Phys 57 787-793 10.1016/S0360-3016(03)00661-8 14529785 1:CAS:528:DC%2BD3sXns12rtrs%3D
57. EK Rowinsky 1999 Novel radiation sensitizers targeting tissue hypoxia Oncology (Huntingt) 13 61-70 1:STN:280:DC%2BD3c%2FhvVCqsw%3D%3D
58. R Roskoski Jr 2004 The ErbB/HER receptor protein-tyrosine kinases and cancer Biochem Biophys Res Commun 319 1-11 10.1016/j.bbrc.2004.04.150 15158434 1:CAS:528:DC%2BD2cXkt1Cgtbg%3D
59. F Ciardiello 2000 Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents Drugs 60 (Suppl 1) 25-32 11129169 1:CAS:528:DC%2BD3cXptVegtr0%3D discussion 41-42
60. F Ciardiello G Tortora 2001 A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor Clin Cancer Res 7 2958-2970 11595683 1:CAS:528:DC%2BD3MXnvF2ktbk%3D
61. ER Wood AT Truesdale OB McDonald D Yuan A Hassell SH Dickerson B Ellis C Pennisi E Horne K Lackey KJ Alligood DW Rusnak TM Gilmer L Shewchuk 2004 A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells Cancer Res 64 6652-6659 10.1158/0008-5472.CAN-04-1168 15374980 1:CAS:528:DC%2BD2cXnsFOlu7g%3D
62. RD Rao CD James 2004 Altered molecular pathways in gliomas: An overview of clinically relevant issues Semin Oncol 31 595-604 15497113 1:CAS:528:DC%2BD2cXhtVSgtLfM
63. NA Lokker CM Sullivan SJ Hollenbach MA Israel NA Giese 2002 Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: Evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors Cancer Res 62 3729-3735 12097282 1:CAS:528:DC%2BD38XltF2jtbs%3D
64. AB Lassman 2004 Molecular biology of gliomas Curr Neurol Neurosci Rep 4 228-233 15102349
65. PS Mischel TF Cloughesy 2003 Targeted molecular therapy of GBM Brain Pathol 13 52-61 12580545
66. T Kilic JA Alberta PR Zdunek M Acar P Iannarelli T O'Reilly E Buchdunger PM Black CD Stiles 2000 Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class Cancer Res 60 5143-5150 11016641 1:CAS:528:DC%2BD3cXntVamur4%3D
67. P Traxler G Bold E Buchdunger G Caravatti P Furet P Manley T O'Reilly J Wood J Zimmermann 2001 Tyrosine kinase inhibitors: From rational design to clinical trials Med Res Rev 21 499-512 10.1002/med.1022 11607931 1:CAS:528:DC%2BD3MXotVeht7c%3D
68. A Mauro A Bulfone E Turco D Schiffer 1991 Coexpression of platelet-derived growth factor (PDGF) B chain and PDGF B-type receptor in human gliomas Childs Nerv Syst 7 432-436 10.1007/BF00263184 1665101 1:STN:280:By2C28zptVc%3D
69. MC Heinrich DJ Griffith BJ Druker CL Wait KA Ott AJ Zigler 2000 Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor Blood 96 925-932 10910906 1:CAS:528:DC%2BD3cXltlKitLw%3D
70. MS Boguski F McCormick 1993 Proteins regulating Ras and its relatives Nature 366 643-654 10.1038/366643a0 8259209 1:CAS:528:DyaK2cXnt1SisQ%3D%3D
71. G Bollag F McCormick 1991 Regulators and effectors of ras proteins Annu Rev Cell Biol 7 601-632 10.1146/annurev.cb.07.110191.003125 1667084 1:CAS:528:DyaK38XltlOmtA%3D%3D
72. NL Tuzi DJ Venter S Kumar SL Staddon NR Lemoine WJ Gullick 1991 Expression of growth factor receptors in human brain tumours Br J Cancer 63 227-233 1671751 1:STN:280:By6C2crhtVU%3D
73. JL Bos J Rooij de KA Reedquist 2001 Rap1 signalling: Adhering to new models Nat Rev Mol Cell Biol 2 369-377 10.1038/35073073 11331911 1:CAS:528:DC%2BD3MXjs1Chu7g%3D
74. A Guha MM Feldkamp N Lau G Boss A Pawson 1997 Proliferation of human malignant astrocytomas is dependent on Ras activation Oncogene 15 2755-2765 10.1038/sj.onc.1201455 9419966 1:CAS:528:DyaK1cXmtVOg
75. MM Feldkamp N Lau A Guha 1999 Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects Oncogene 18 7514-7526 10.1038/sj.onc.1203105 10602510 1:CAS:528:DC%2BD3cXpslah
76. X Wang DC Christiani EJ Mark H Nelson JK Wiencke L Gunn JC Wain KT Kelsey 1999 Carcinogen exposure, p53 alteration, and K-ras mutation in synchronous multiple primary lung carcinoma Cancer 85 1734-1739 10.1002/ (SICI)1097-0142(19990415)85:8<1734::AID-CNCR13>3.0.CO;2-1 10223567 1:STN:280:DyaK1M3jvVSkug%3D%3D
77. ZJ Liu R Snyder A Soma T Shirakawa BL Ziober RM Fairman M Herlyn OC Velazquez 2003 VEGF-A and alphaVbeta3 integrin synergistically rescue angiogenesis via N-Ras and PI3-K signaling in human microvascular endothelial cells Faseb J 17 1931-1933 14519669 1:CAS:528:DC%2BD3sXot1Kit70%3D
78. KN Meadows P Bryant PA Vincent KM Pumiglia 2004 Activated Ras induces a proangiogenic phenotype in primary endothelial cells Oncogene 23 192-200 10.1038/sj.onc.1206921 14712224 1:CAS:528:DC%2BD2cXhtlGisA%3D%3D
79. M Alsina R Fonseca EF Wilson AN Belle E Gerbino T Price-Troska RM Overton G Ahmann LM Bruzek AA Adjei SH Kaufmann JJ Wright D Sullivan B Djulbegovic AB Cantor PR Greipp WS Dalton SM Sebti 2004 Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma Blood 103 3271-3277 10.1182/blood-2003-08-2764 14726402 1:CAS:528:DC%2BD2cXjslKgsLo%3D
80. P Carmeliet 2003 Angiogenesis in health and disease Nat Med 9 653-660 10.1038/nm0603-653 12778163 1:CAS:528:DC%2BD3sXktFOntbY%3D
81. M Tjwa A Luttun M Autiero P Carmeliet 2003 VEGF and PlGF: Two pleiotropic growth factors with distinct roles in development and homeostasis Cell Tissue Res 314 5-14 10.1007/s00441-003-0776-3 13680354 1:CAS:528:DC%2BD3sXos1Clsr4%3D
82. D Wang HJ Huang A Kazlauskas WK Cavenee 1999 Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase Cancer Res 59 1464-1472 10197615 1:CAS:528:DyaK1MXisVWktb8%3D
83. MS Pepper SJ Mandriota M Jeltsch V Kumar K Alitalo 1998 Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity J Cell Physiol 177 439-452 10.1002/ (SICI)1097-4652(199812)177:3<439::AID-JCP7>3.0.CO;2-2 9808152 1:CAS:528:DyaK1cXnsVKjtr0%3D
84. T Sanchez-Elsner LM Botella B Velasco A Corbi L Attisano C Bernabeu 2001 Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression J Biol Chem 276 38527-38535 10.1074/jbc.M104536200 11486006 1:CAS:528:DC%2BD3MXnvVensbg%3D
85. PC Brooks AM Montgomery M Rosenfeld RA Reisfeld T Hu G Klier DA Cheresh 1994 Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels Cell 79 1157-1164 10.1016/ 0092-8674(94)90007-8 7528107 1:CAS:528:DyaK2MXivVWqu7o%3D
86. B Gesundheit G Klement C Senger R Kerbel M Kieran S Baruchel L Becker 2003 Differences in vasculature between pilocytic and anaplastic astrocytomas of childhood Med Pediatr Oncol 41 516-526 10.1002/mpo.10308 14595708
87. KH Plate W Risau 1995 Angiogenesis in malignant gliomas Glia 15 339-347 10.1002/glia.440150313 8586468 1:STN:280:BymC2Mjltlw%3D
88. KH Plate HD Mennel 1995 Vascular morphology and angiogenesis in glial tumors Exp Toxicol Pathol 47 89-94 7580112 1:STN:280:BymC3czjvF0%3D
89. B Millauer MP Longhi KH Plate LK Shawver W Risau A Ullrich LM Strawn 1996 Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo Cancer Res 56 1615-1620 8603410 1:CAS:528:DyaK28XitVemtr4%3D
90. JK Smith NM Mamoon RJ Duhe 2004 Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy Oncol Res 14 175-225 14977353
91. M Zangari E Anaissie A Stopeck A Morimoto N Tan J Lancet M Cooper A Hannah G Garcia-Manero S Faderl H Kantarjian J Cherrington M Albitar FJ Giles 2004 Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma Clin Cancer Res 10 88-95 14734456 1:CAS:528:DC%2BD2cXkvF2qsg%3D%3D
92. J Litz G Sakuntala Warshamana-Greene G Sulanke KE Lipson GW Krystal 2004 The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression Lung Cancer 46 283-291 10.1016/j.lungcan.2004.05.005 15541812
93. J Renbarger A Aleksic L McGuffey R Dauser S Berg S Blaney 2004 Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates Cancer Chemother Pharmacol 53 39-42 10.1007/s00280-003-0683-z 14551735 1:CAS:528:DC%2BD3sXpsVGitL8%3D
94. WM Stadler D Cao NJ Vogelzang CW Ryan K Hoving R Wright T Karrison EE Vokes 2004 A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer Clin Cancer Res 10 3365-3370 15161690 1:CAS:528:DC%2BD2cXkt1GhsLw%3D
95. WF Westlin 2001 Integrins as targets of angiogenesis inhibition Cancer J 7 Suppl 3 S139-S143 11779085
96. SN Nikolopoulos P Blaikie T Yoshioka W Guo FG Giancotti 2004 Integrin beta4 signaling promotes tumor angiogenesis Cancer Cell 6 471-483 10.1016/j.ccr.2004.09.029 15542431 1:CAS:528:DC%2BD2cXhtVGlurjM
97. H Hall JA Hubbell 2004 Matrix-bound sixth Ig-like domain of cell adhesion molecule L1 acts as an angiogenic factor by ligating alphavbeta3-integrin and activating VEGF-R2 Microvasc Res 68 169-178 10.1016/j.mvr.2004.07.001 15501236 1:CAS:528:DC%2BD2cXovVKrsLY%3D
98. TA Springer JH Wang 2004 The three-dimensional structure of integrins and their ligands, and conformational regulation of cell adhesion Adv Protein Chem 68 29-63 15500858 1:CAS:528:DC%2BD2MXosF2rtA%3D%3D
99. R Hwang J Varner 2004 The role of integrins in tumor angiogenesis Hematol Oncol Clin North Am 18 vii 991-1006 15474331
100. TJ MacDonald T Taga H Shimada P Tabrizi BV Zlokovic DA Cheresh WE Laug 2001 Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist Neurosurgery 48 151-157 11152340 1:STN:280:DC%2BD3M7jvVantA%3D%3D
101. S Chatterjee A Matsumura J Schradermeier GY Gillespie 2000 Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents J Neurooncol 46 135-144 10.1023/A:1006444300504 10894366 1:STN:280:DC%2BD3M%2Fhs1OntQ%3D%3D
102. S Kumar TE Witzig SV Rajkumar 2002 Thalidomide as an anti-cancer agent J Cell Mol Med 6 160-174 12169202 1:CAS:528:DC%2BD38Xmt1Gmtbw%3D
103. JM Jacobson 2000 Thalidomide: A remarkable comeback Expert Opin Pharmacother 1 849-863 10.1517/14656566.1.4.849 11249521 1:CAS:528:DC%2BD3cXktlalt7Y%3D
104. D Stirling 2001 Thalidomide: A novel template for anticancer drugs Semin Oncol 28 602-606 10.1016/S0093-7754(01)90032-6 11740817 1:CAS:528:DC%2BD38XjvVSmtw%3D%3D
105. HA Fine WD Figg K Jaeckle PY Wen AP Kyritsis JS Loeffler VA Levin PM Black R Kaplan JM Pluda WK Yung 2000 Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas J Clin Oncol 18 708-715 10673511 1:CAS:528:DC%2BD3cXhs1akurw%3D
106. P Richardson K Anderson 2004 Immunomodulatory analogs of thalidomide: An emerging new therapy in myeloma J Clin Oncol 22 3212-3214 10.1200/ JCO.2004.05.984 15249587 1:CAS:528:DC%2BD2cXpsVGrs7c%3D
107. TM Tohnya SS Ng WL Dahut JJ Wright PM Arlen JL Gulley C Parker J Zeldis WD Figg 2004 A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer Clin Prostate Cancer 2 241-243 15072608 1:CAS:528:DC%2BD2cXktlChtrw%3D
108. B Sirohi R Powles 2004 Multiple myeloma Lancet 363 875-887 10.1016/ S0140-6736(04)15736-X 15031034
109. B Barlogie 2003 Thalidomide and CC-5013 in multiple myeloma: The University of Arkansas experience Semin Hematol 40 33-38 15015894 1:CAS:528:DC%2BD2cXmvVeitQ%3D%3D
110. JB Bartlett A Michael IA Clarke K Dredge S Nicholson H Kristeleit A Polychronis H Pandha GW Muller DI Stirling J Zeldis AG Dalgleish 2004 Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers Br J Cancer 90 955-961 10.1038/sj.bjc.6601579 14997189 1:CAS:528:DC%2BD2cXhslWrs7o%3D
111. C Guerin A Olivi JD Weingart HC Lawson H Brem 2004 Recent advances in brain tumor therapy: Local intracerebral drug delivery by polymers Invest New Drugs 22 27-37 10.1023/B:DRUG.0000006172.65135.3e 14707492 1:CAS:528:DC%2BD3sXptlyrtr8%3D
112. IR Whittle S Lyles M Walker 2003 Gliadel therapy given for first resection of malignant glioma: A single centre study of the potential use of Gliadel Br J Neurosurg 17 352-354 10.1080/0268869031000108873 14579902 1:STN:280:DC%2BD3srgt1ChsA%3D%3D
113. H Brem P Gabikian 2001 Biodegradable polymer implants to treat brain tumors J Control Release 74 63-67 10.1016/S0168-3659(01)00311-X 11489483 1:CAS:528:DC%2BD3MXlslansr0%3D
114. X Yuan K Tabassi JA Williams 1999 Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma Radiat Oncol Investig 7 218-230 10.1002/ (SICI)1520-6823(1999)7:4<218::AID-ROI3>3.0.CO;2-C 10492162 1:CAS:528:DyaK1MXmtlWruro%3D
115. JN Bruce A Falavigna JP Johnson JS Hall BD Birch JT Yoon EX Wu RL Fine AT Parsa 2000 Intracerebral clysis in a rat glioma model Neurosurgery 46 683-691 10719865 1:STN:280:DC%2BD3c7ot1Ortg%3D%3D
116. M Kawakami K Kawakami RK Puri 2003 Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy J Neurooncol 65 15-25 10.1023/A:1026294416718 14649882
117. DM Lieberman DW Laske PF Morrison KS Bankiewicz EH Oldfield 1995 Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion J Neurosurg 82 1021-1029 7539062 1:CAS:528:DyaK2MXmsVGmsL8%3D
118. F Weber A Asher R Bucholz M Berger M Prados S Chang J Bruce W Hall NG Rainov M Westphal RE Warnick RW Rand F Floeth F Rommel H Pan VN Hingorani RK Puri 2003 Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma J Neurooncol 64 125-127 10.1023/A:1024901501173 12952293
119. I Pastan V Chaudhary DJ FitzGerald 1992 Recombinant toxins as novel therapeutic agents Annu Rev Biochem 61 331-354 10.1146/ annurev.bi.61.070192.001555 1497314 1:CAS:528:DyaK38Xls1ehsrY%3D
120. WA Hall A Godal S Juell O Fodstad 1992 In vitro efficacy of
121. DJ FitzGerald I Pastan 1992 Pseudomonas exotoxin: Recombinant conjugates as therapeutic agents Biochem Soc Trans 20 731-734 1487051 1:CAS:528:DyaK38XlsVakt78%3D
122. SJ Danson MR Middleton 2001 Temozolomide: A novel oral alkylating agent Expert Rev Anticancer Ther 1 13-19 10.1586/14737140.1.1.13 12113120 1:CAS:528:DC%2BD3MXltlSgtLc%3D
123. Y Cai MH Wu M Xu-Welliver AE Pegg SM Ludeman ME Dolan 2000 Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases Cancer Res 60 5464-5469 11034089 1:CAS:528:DC%2BD3cXns1ehtro%3D
124. AE Pegg 2000 Repair of O(6)-alkylguanine by alkyltransferases Mutat Res 462 83-100 10767620 1:CAS:528:DC%2BD3cXisVKgsbs%3D
125. HS Friedman RE McLendon T Kerby M Dugan SH Bigner AJ Henry DM Ashley J Krischer S Lovell K Rasheed F Marchev AJ Seman I Cokgor J Rich E Stewart OM Colvin JM Provenzale DD Bigner MM Haglund AH Friedman PL Modrich 1998 DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma J Clin Oncol 16 3851-3857 9850030 1:CAS:528:DyaK1MXos1Si
126. HS Friedman SP Johnson Q Dong SC Schold BK Rasheed SH Bigner F Ali-Osman E Dolan OM Colvin P Houghton G Germain JT Drummond S Keir S Marcelli DD Bigner P Modrich 1997 Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft Cancer Res 57 2933-2936 9230204 1:CAS:528:DyaK2sXkslOktbw%3D
127. M Belanich T Randall MA Pastor JT Kibitel LG Alas ME Dolan SC Schold Jr M Gander FJ Lejeune BF Li AB White P Wasserman ML Citron DB Yarosh 1996 Intracellular localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase Cancer Chemother Pharmacol 37 547-555 10.1007/s002800050427 8612308 1:CAS:528:DyaK28XisVCqu74%3D
128. RB Mitchell ME Dolan 1993 Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis (2-chloroethyl)-1-nitrosourea Cancer Chemother Pharmacol 32 59-63 8462125 1:CAS:528:DyaK3sXlsleksr4%3D
129. HS Friedman S Keir AE Pegg PJ Houghton OM Colvin RC Moschel DD Bigner ME Dolan 2002 O6-benzylguanine-mediated enhancement of chemotherapy Mol Cancer Ther 1 943-948 12481416 1:CAS:528:DC%2BD3sXmvFOntw%3D%3D
130. HS Friedman DM Kokkinakis J Pluda AH Friedman I Cokgor MM Haglund DM Ashley J Rich ME Dolan AE Pegg RC Moschel RE McLendon T Kerby JE Herndon DD Bigner SC Schold Jr 1998 Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma J Clin Oncol 16 3570-3575 9817277 1:CAS:528:DyaK1cXnsVOgtrc%3D
131. ST Keir ME Dolan AE Pegg A Lawless RC Moschel DD Bigner HS Friedman 2000 O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer-central nervous system tumor xenografts-implications for clinical trials Cancer Chemother Pharmacol 45 437-440 10.1007/s002800051016 10854129 1:CAS:528:DC%2BD3cXislaqu78%3D